Music

Donate

Make a Donation

The Ketamine Research Foundation is a registered 501(c)(3).

We build staff as projects mature and needs are delineated.

Donations may be earmarked for projects the donor wishes to support and otherwise will be applied at the discretion of KRF to core structural needs or to project support. Overhead is deliberately kept low to maximize the potency of donations.

Support our transformative work by making a donation. To donate via credit card or Paypal click the “Make A Donation” button below. 

To make a donation via check, please mail to:

The Ketamine Research Foundation
6 Crest Avenue
San Anselmo, CA 94960

2023 Funding Goals

Realizing KRF’s Potential in 2023 

KRF excels in Research, Education and Training with Ketamine, Ketamine Assisted Psychotherapy and Psychoactive and Psychedelic Methodologies

OUR PLATFORM:

  • KRF is the leading ketamine assisted psychotherapy organization in the world.
  • We have developed as the free-standing research organization developing the options for utilizing ketamine to benefit human beings.
  • We are the preeminent training organization with over 900 practitioners trained. We are producing Eight or more major programs in 2023-2024 including bringing KAP to Israel, Europe-Barcelona, Mexico, Australia, and South America.
  • Our Ketamine Training Center is originating new programs to access KAP with our advanced trainings and our dharma-k exploration of the integration of spirit and spiritual practices with the meditative expansiveness of the ketamine experience.
  • Our Ketamine Psychotherapy Associates (KPA) membership organization has grown to over 100 practitioners with new members joining frequently
  • We remain the only organization with access to care available to KPA members offering financial support to those who cannot afford treatment.
  • We are publishing our work and generating public awareness. Recognition of KRF is growing rapidly.
  • We have opened the door to treating adolescents and their families with our recent publication in frontiers of psychiatry
  • We are in a relationship with progressive ‘Therapeutics Inc (PTI), which shares development perspectives, patent, and mutual assistance. 

Overall Objectives for 2023

Our Research Programs and their Funding Goals

Overview: As we are able to design and perform research within the legal status of ketamine—WHO/worldwide –we are in the process of developing protocols to be funded and administered under KRF’s non-profit umbrella. We are welcoming of new creative initiatives and are developing relations with collaborating researchers. Each project has its own cost center and donations to KRF may be earmarked. Studies are IRB approved and registered.

Our New Initiative – in Formation: 

Protocol for Ketamine Treatment of Acute Emotional Trauma and Distress

The International Consultation Group for the Treatment of Acute Trauma with Ketamine and Other Therapeutic Modalities (ICG).

In awareness of ketamine’s potential for the treatment of acute agitation, suicidality, and PTSD, and in response to the many horrors being visited on humans, we have just begun the development of ketamine protocols for the treatment of emotional reactions to acute traumatization. We have sent out our initial protocol as widely as possible in an effort to provide a guide to ketamine’s use as a therapeutics applicable to acute trauma. KRF is serving as an initiator and a ground to which practitioners may turn. This is a collaboration and to that end we are building an international body, what we are calling the ICG, to create the conditions for applying ketamine and other modalities for acute care. This is unprecedented and we are in need of developing a literature to validate our methodology. Developing the protocol with intensive feedback from those on the ground is essential. This is a cooperative project and will grow in its scope and needs. It is created in the spirit of service and beyond borders with the intention of caring, kindness and sharing. We are directly supporting trauma work with ketamine in the Ukraine. Our attempt to provide trauma training with ketamine in Israel/Plaestine continues—with difficulty.. 

$35,000 initial budget   

 

Ketamine for Menstrually Related Disorders—PMS and PMDD

KRF has focused on Women’s Health and wellbeing with a new project to demonstrate the effectiveness of ketamine for PMS and PMDD. We are pleased to report that we are successfully navigating the FDA IND approval process and have breakthroughs in the first use of sublingual lozenges with esketamine and at home use of esketamine in this low does format based on treating the symptoms of PMDD as they arise. Previously, based on our clinical experience through our sister Center for Transformational Psychotherapy, we conducted a small study demonstrating the extraordinary effectiveness of low dose ketamine given in response to the arising of symptoms of PMS/PMDD. This led to a use patent for this indication, the benefit of patenting being widespread access. It is our strong belief that women worldwide will benefit from episodic use on an intermittent basis with provision for at-home administration as needed, This is a breakthrough for women suffering in the luteal phase of the menstrual cycle providing a restitution of well-being and presence.

$200,000 is our budget 

 

The Pharmacokinetics of the Sublingual Lozenge

The sublingual lozenge (SL) that is in widespread clinical use, much of it controversial with respect to standard of care—FDA just issued a warning about this—was developed by Phil Wolfson in collaboration for its formulation with Peter Koshland. The formula was offered freely and has been replicated and has had dosage augmentation by some. We have always favored the SL form over the intranasal form as it has minimal abuse potential. Its absorption through the mucosal linings of the mouth depends on the length of time it is held there. Various recommendations have been made for duration, some of them in the interest of selling more product.  Our consistent recommendation has been for 15 minutes. Essential to our research and our clinical practice—and as a data based recommendation based on our findings, we are preparing to conduct a pharmacokinetic study, utilizing the lab at UCSF for our analytics, as we did for the Lactation Study. The study undoubtedly will benefit research and clinical practices as well as inform the public about standard of care.

$200,000 is our budget 

                                                                                                                                                     The Post-Partum Depression Protocol

The Foundation has patented the use of ketamine for Post-Partum Depression (PPD) which is novel.  We are developing commercialization with an exclusive contract with PTI for which we have received equity. We are in protocol development for a multi-site PPD KAP model treatment program which we believe will demonstrate great success in benefitting new mothers without affecting breast feeding or exposing infants to medications. Our groundbreaking ketamine and lactation study has assured us of this. Anticipated project initiation is in Spring 2024. There Is great interest in this as a significant new treatment for women suffering with PPD.

 $1,000,000 is our budget

 

The Veterans Co-Facilitator Training Program in coalition with Heroic Hearts

Will move into operation at the beginning of 2024. This is a major and unique initiative to transform the treatment of PTSD for vets using a KAP group model in a 3-month long experience to develop vets themselves to be co-facilitators for an expanded PTSD program that is facilitated by those who have military experience. As we move to Phase 2 our intention is to have this serve as a demonstration affecting positively the treatment of vets by the VA and other institutions. Goal $200,000.

We have redesigned our logo and websites and developing funding campaigns and public awareness of who we are and what we do.

All of this goes to our need for basic structure. We are a lean outfit. We build staff as projects mature and needs are delineated. As our programs grow and are activated, we are in need of new staff and the stuff of making an organization thrive. We appreciate donations that contribute to our structure.

 

KRF Structure and Funding Goals

  • Access to Care $100,000—available to our practitioners who are members of KPA.  See the information on the KRF site for this unique support for patients who cannot afford fees for KAP.
  • Ketamine Library now rebuilt with public access  $15,000
  • The Ketamine Training Center—self-supporting
  • The BIPOC scholarship support program—in collaboration with The Trauma Research Foundation and Individual Supporters—for diversity in the psychedelic space—A first BIPOC program will occur this coming April at Menla Retreat Center $50,000
  • Ketamine Psychotherapy Associates (KPA): A Program of KRF supporting KAP and KAP Practices Internationally. Supported entirely by membership fees and continually growing in numbers. We have over 100 practitioners developing their KAP programs across the U.S. — included in KPA is the Ketamine Data Project—the seminal source for collecting data and reporting it for KAP and growing our clinical knowledge of ketamine’s effects, problems, and outcomes.
  • The KAP Music Library—An expanding Playlist Library for Patient and Practitioner Use in Support of KAP sessions– by a group of our musicologists.

 
Our Program: 

  • Develop through research and clinical applications, the arising awareness of the potentialities and applications of ketamine for human benefits.
  • Develop and foster the treatment of acute trauma with emotional distress, and potential resultant PTSD.
  • Building our teams to foster research, organization, and corporate development.
  • Funding of our programs—those in process and those emerging.
  • Foster an awareness of who we are and what we do.
  • Continue to articulate the standard of care for ketamine practices.
  • Continue to uphold the ethical practice of KAP with our Guidelines.
  • Expand and continually modify our training programs and our KPA organization.
  • Bring KAP and ketamine practice abroad with training, consultation, and support for arising practices.
  • Build coalitions with sister organizations.
  • Continue our openness to creativity, new initiatives, and development of all possible elements of KAP practice
  • Publish a massive review of KAP practice based on our digitized Redcap program. Publish research and KAP methodology.
  • Lead the field in excellence, ethics and standard of care
  • Participate in the awakening to psychedelic assisted psychotherapy       

There is much more in process, and we encourage donors to participate in our work and become familiar with what we do and who we are.

Your donations are greatly appreciated!

Hugs and love,
Phil Wolfson MD — Founder and CEO